News and Trends 3 Nov 2022 Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial Servier and French biotech company OSE Immunotherapeutics SA have completed patient enrollment in a phase 2a clinical trial evaluating the efficacy and safety of monoclonal antibody OSE-127/S95011 in primary Sjögren’s syndrome. The international, randomized, double-blind, placebo-controlled, phase 2a study is designed to evaluate the efficacy and tolerance of the monoclonal antibody OSE-127/S95011 in primary Sjögren’s […] November 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 Authorization given to BeiGene’s chemo-free treatment option for lymphoma Marketing authorization has been granted to a drug to treat relapsed/refractory (R/R) marginal zone lymphoma (MZL) without chemotherapy, it was announced today (November 2). The European Commission (EC) gave the authorization to biotech company, BeiGene, for Brukinsa (zanubrutinib), which treats adults with the condition who have received at least one prior anti-CD20-based therapy. The approval […] November 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 CV6 Therapeutics raises $9.2M to test cancer drug CV6 Therapeutics has secured $9.2m to progress its lead oncology asset, CV6-168, into a first-in-human phase 1a clinical trial and perform further scientific development work. CV6 Therapeutics is a drug development biotechnology company specializing in innovative small molecule therapeutics for cancer and inflammatory diseases. Investors participating in the financing include QUBIS, the commercialization arm of […] November 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 AELIX Therapeutics publishes positive data on its HIV vaccine Positive results from a clinical study into biotech company, AELIX’ Therapeutics’, HIV vaccine have been published in Nature Medicine journal. The announcement came today (November 2) from the Spanish-based company that specializes in developing immunotherapies for HIV infection. Christian Brander, co-founder and chief scientific officer at AELIX, said: “We are excited to have published the […] November 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 31 Oct 2022 New drug application for chronic kidney disease sparks $35M milestone payment A submission has been made for a new drug application by Japanese Kyowa Kirin Co. Ltd. for the improvement of hyperphosphatemia in patients with chronic kidney disease (CKD). The company has submitted the application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for tenapanor, which helps those with CKD on dialysis. Ardelyx, Inc. […] October 31, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2022 First patient enrolled and dosed on expansion phase of cancer treatment trial The first patient in an expansion phase of a trial looking at cancer drug Modi-1 has been enrolled and dosed. Scancell Holdings plc, the developer of immunotherapies for the treatment of cancer and infectious disease made the announcement today (October 31). The expansion phase is part of the monotherapy arms of the phase 1 clinical […] October 31, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2022 AKT inhibitor shows signs of effectiveness in patient trial In a trial matching new treatments to cancer patients based on the genetic make-up of their tumors, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumors shrink. This included patients with breast cancer and endometrial cancer as well as two rarer forms – anal and salivary gland. In the majority […] October 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 26 Oct 2022 Study shows ability to develop and apply targeted treatment in head and neck cancers A joint study looked at the development identification of specific markers to improve risk assessment of patients with difficult to treat head and neck tumors. Malignant tumors in these areas are very heterogeneous and have a lack of prognostic markers – a significant impediment to personalized treatment. The joint study by MedUni Vienna and the […] October 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 First patient dosed in trial to assess predictive performance of immuno-oncology therapy The first patient has been dosed at the Macquarie University Hospital in Sydney as part of a clinical trial to evaluate whether a drug can predict patient response to immuno-oncology therapy targeting a number of solid tumor types. ImaginAb Inc. is a biotech company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation […] October 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Inotrem study for the treatment of critically ill COVID-19 patients meets endpoints Inotrem has announced positive results for ESSENTIAL, its phase II clinical trial in COVID-19 patients hospitalized in critical care units and experiencing acute respiratory distress. The French clinical stage biotech company specializes in immunotherapies for acute and chronic inflammatory syndromes. The announcement was made at the European Society of Intensive Care Medicine’s Annual Congress, held […] October 26, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 24 Oct 2022 Sensorion gets go-ahead from France for trial of drug to prevent hearing loss Biotech company, Sensorion, today (October 24) announced that the initiation of a proof of concept (PoC) clinical trial of SENS-401 (Arazasetron) in patients with Cisplatin-Induced Ototoxicity (CIO) has been approved by the regulatory authorities in France. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies […] October 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2022 Domain Therapeutics to start clinical trials of solid tumor treatment Domain Therapeutics says its immuno-oncology candidate has been cleared in Belgium and France, leading to a phase I clinical trial. It has cleared its clinical trial applications with the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) in France and the AFMPS (Agence Fédérale des Médicaments et des Produits de Santé) […] October 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email